ADMA Biologics
ADMA · Biotechnology
$10.68
2.5%Krystal Biotech
KRYS · Biotechnology
$311.50
2.7%The short version
- ADMA Biologics is the larger business, with $510M of revenue in fiscal 2025 against $389M for Krystal Biotech.
- Krystal Biotech grew revenue faster (33.9%, against 19.6%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against 37.5% operating margin).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against 5.5% FCF margin).
- Krystal Biotech earned a higher return on the capital invested in it (43.6%, against 39.5%).
- Investors pay more for each dollar of Krystal Biotech’s earnings: a P/E of 39.0x against 15.3x for ADMA Biologics.
| Latest fiscal year | ADMA · FY25 | KRYS · FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | $9.6B |
| Revenue | $510M | $389M |
| Free cash flow | $27.8M | $189M |
| Net income | $147M | $205M |
| Growth | ||
| Revenue growth | 19.6% | 33.9% |
| 5-year growth | 64.6% | — |
| Share count change | 0.6% | 0.7% |
| Profitability | ||
| Gross margin | 57.4% | — |
| Operating margin | 37.5% | 41.5% |
| Net margin | 28.8% | 52.6% |
| FCF margin | 5.5% | 48.6% |
| Return on capital | 39.5% | 43.6% |
| Return on equity | 35.6% | 18.9% |
| Balance sheet | ||
| Net debt | −$15.5M | −$828M |
| Net debt / EBITDA | −0.1x | −5.0x |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | 39.0x |
| Piotroski F-score | 5 | 5 |
FY16
ADMA $10.7M
KRYS —
FY17
ADMA $22.8M
KRYS —
FY18
ADMA $17.0M
KRYS —
FY19
ADMA $29.3M
KRYS —
FY20
ADMA $42.2M
KRYS —
FY21
ADMA $80.9M
KRYS $0.0M
FY22
ADMA $154M
KRYS $0.0M
FY23
ADMA $258M
KRYS $50.7M
FY24
ADMA $427M
KRYS $291M
FY25
ADMA $510M
KRYS $389M
ADMA
KRYS
FY16
ADMA −162.6%
KRYS —
FY17
ADMA −172.7%
KRYS —
FY18
ADMA −355.0%
KRYS —
FY19
ADMA −141.1%
KRYS —
FY20
ADMA −153.8%
KRYS —
FY21
ADMA −72.1%
KRYS —
FY22
ADMA −25.6%
KRYS —
FY23
ADMA 8.4%
KRYS −216.2%
FY24
ADMA 32.6%
KRYS 22.6%
FY25
ADMA 37.5%
KRYS 41.5%
ADMA
KRYS
FY16
ADMA −$18.3M
KRYS −$1.3M
FY17
ADMA −$40.0M
KRYS −$4.1M
FY18
ADMA −$64.8M
KRYS −$11.7M
FY19
ADMA −$80.0M
KRYS −$25.1M
FY20
ADMA −$115M
KRYS −$40.9M
FY21
ADMA −$126M
KRYS −$116M
FY22
ADMA −$73.4M
KRYS −$154M
FY23
ADMA $4.0M
KRYS −$101M
FY24
ADMA $110M
KRYS $119M
FY25
ADMA $27.8M
KRYS $189M
ADMA
KRYS
FY16
ADMA —
KRYS —
FY17
ADMA —
KRYS —
FY18
ADMA —
KRYS —
FY19
ADMA —
KRYS —
FY20
ADMA −82.2%
KRYS —
FY21
ADMA −29.7%
KRYS −61.2%
FY22
ADMA −15.8%
KRYS −76.9%
FY23
ADMA 8.1%
KRYS −47.7%
FY24
ADMA 52.2%
KRYS 20.7%
FY25
ADMA 39.5%
KRYS 43.6%
ADMA
KRYS
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.